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OBJECTIVE: Chronic skin diseases have a heavy impact
on the physical and mental well-being of the patient. 
This is conﬁrmed by the large number of quality of life
studies that exist. Paradoxically, no study has evaluated
depressive symptomatology in Spanish patients with 
dermatosis. This was why it was decided to carry out, in
association with Accion Psoriasis (a Spanish Patient
Support Group), an evaluation of the depressive symp-
tomatology of patients suffering from psoriasis.
METHODS: The CES-D scale (Center for Epidemiologic
Studies—Depression scale) was developed in the USA at
the National Institute of Mental Health to perform epi-
demiological studies of depressive symptomatology in the
general population. The CES-D scale was sent to 1300
patients with psoriasis, members or supporters of Accion
Psoriasis. The completed questionnaires were returned in
prepaid envelopes. RESULTS: Out of the 1300 question-
naires sent out in March 2003. At mid-March 2003, 300
questionnaires were returned: response rate 23%. The
presented results concerned the 106 ﬁrst questionnaires
analysed. The male/female gender ratio was as follows
54/46. Depressive symptomatology was observed in 
44% of men (average score 17.8) and 55% of women
(average score 21). This difference between men and
women was not statistically signiﬁcant. An evaluation
according to the age at diagnosis was also carried out: 2
groups were identiﬁed: diagnosis at 16 years of age or
younger versus a group diagnosed after the age of 16.
Depressive symptomatology was observed in 54% of
patients in the ﬁrst group versus 46% of patients in the
second group. CONCLUSION: These preliminary results
show the importance of the psychological impact of 
dermatosis, especially psoriasis. Global management of
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OBJECTIVE: Chronic skin diseases have a heavy impact
on the physical and mental well-being of the patient. This
is conﬁrmed by the large number of quality of life studies
that exist. Paradoxically, no study has evaluated depres-
sive symptomatology in Italian patients with dermatosis.
This was why it was decided to carry out, in association
with ADIPSO (an Italian Patient Support Group), an eval-
uation of the depressive symptomatology of patients suf-
fering from psoriasis. Tools: the CES-D scale (Center for
Epidemiologic Studies—Depression scale) was developed
in the USA at the National Institute Of Mental Health to
perform epidemiological studies of depressive symptoma-
tology in the general population. METHOD: The CES-D
scale was remitted by Italian Dermatologists to the ﬁrst
5000 patients with psoriasis coming to their ofﬁce. The
completed questionnaires were returned in prepaid
envelopes. RESULTS: Out of the 5000 questionnaires
remitted in February and March 2003. At mid-March
2003, 3000 questionnaires were returned: response rate
60%. The presented results concerned the 100 ﬁrst ques-
tionnaires analysed. The male/female gender ratio was as
follows 61/39. Depressive symptomatology was observed
in 34% of men (average score 17.2) and 62% of women
(average score 21). This difference between men and
women was statistically signiﬁcant (p = 0.007). An eval-
uation according to the education level was also carried
out: Two groups were identiﬁed: patients having a
primary/secondary education level (n = 69) versus pa-
tients having a higher education level (n = 31). Depres-
sive symptomatology was observed in 51% of patients in
the ﬁrst group versus 32% of patients in the second
group. This difference according to the education level
was statistically signiﬁcant (p < 0.02). CONCLUSION:
These preliminary results show the importance of the 
psychological impact of dermatosis, especially psoriasis.
Global management of patients seems essential for
patients suffering from chronic dermatosis.
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OBJECTIVES: Attention deﬁcit/hyperactivity disorder
(ADHD) is a behavioral disorder, originating in child-
hood, with broad impairment in academic performance,
social functioning, and quality of life. ADHD health state
utilities have not previously been assessed using parent
ratings. Health state utilities are needed to calculate
quality-adjusted life years (QALYs), a critical measure of
outcomes in cost-effectiveness studies. The purpose of this
study was to use standard gamble (SG) utility methodol-
ogy to assess parent preferences for ADHD health states.
METHODS: Parents of children diagnosed with ADHD
completed SG utility interviews, in which they rated their
child’s current health and 11 hypothetical health states
(e.g., untreated ADHD; stimulant treatment; atomoxetine
treatment, a new non-stimulant). The hypothetical health
states were developed based on physician interviews, pub-
lished literature, and unpublished clinical trial data.
Parents reported children’s symptoms using the 18-item
ADHD-RS. Construct validity and health state differences
were examined with correlations, t-tests, and ANOVAs.
RESULTS: Participants were 43 parents of children with
ADHD. The mean parent SG rating of their child’s
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current health state was 0.74 (possible utility scores range
from 0 to 1). Current health ratings were signiﬁcantly cor-
related with inattentive, hyperactive, and overall symp-
toms of ADHD (0.37, 0.36, and 0.40; p < 0.05). SG
ratings of hypothetical health states ranged from 0.48
(severe untreated ADHD) to 0.88 (effective, tolerable ato-
moxetine treatment). Comparisons between health states
found expected differences between untreated mild, mod-
erate, and severe ADHD health states. When both treat-
ments were effective and tolerable, parents preferred
atomoxetine to stimulants (p < 0.03). CONCLUSIONS:
SG ratings of current health demonstrated construct
validity through signiﬁcant correlations with ADHD
symptoms. Statistical comparisons revealed signiﬁcant
differences between treatment-related health states. In
sum, parent SG interviews appear to be a valid method
for obtaining utility scores that can be used in cost-
effectiveness models of ADHD treatment.
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OBJECTIVES: Major depressive disorder (MDD) is asso-
ciated with impaired patient functioning and signiﬁcant
reductions in health-related quality of life (HRQL). Anti-
depressant treatments aim to increase patient rates of sus-
tained remission as early as possible, and our objective
was to study the impact of early sustained remission on
patient’s HRQL. METHODS: A total of 250 patients
with a DSM-IV diagnosis of MDD under treatment with
selective serotonin reuptake inhibitors were selected for
an observational 8-week follow-up study. Patient assess-
ments included the Montgomery-Asberg Depression
Rating Scale (MADRS), the Short Form-36 Item scale (SF-
36) and the EuroQoL (EQ-5D). The MADRS was per-
formed at baseline, weeks 2, 3, 4, and 8 and HRQL scales
were performed at baseline and week 8. Remission was
deﬁned using the MADRS cut-off value of 12. Five sub-
groups were deﬁned: remitters at week 2 (G1), week 3
(G2), week 4 (G3), week 8 (G4) and non-remitters at
week 8 (G5). Multivariate analyses of variance were used
to assess the differences of HRQL among these groups
after adjustment on centre and baseline MADRS scores.
RESULTS: The distribution of patients across groups was
6.7% (G1), 16.8% (G2), 12.4% (G3), 21.2% (G4) and
42.9% (G5). After adjustment, HRQL assessed by EQ-
5D was signiﬁcantly higher for remitters (G1: 0.81 ± 0.08;
G2: 0.79 ± 0.16; G3: 0.77 ± 0.20; G4: 0.71 ± 0.21; G5:
0.57 ± 0.28; p < 0.001). The same results were found with
the SF-36 Physical and Mental Composite Summary
scores (p < 0.001 for both) as well as SF-36 subscales 
(p < 0.001). Early sustained remitters reported higher EQ-
5D scores (G1 and G2 versus G3 and G4, p < 0.05).
CONCLUSION: The results of this observational study
clearly show the major impact of sustained remission on
HRQL in MDD. Time to sustained remission may have
a major impact on patient’s HRQL and might become a
pre-requisite for approval and reimbursement of new
antidepressant compounds.
PMH25
ASSESSING HEALTH-RELATED QUALITY OF
LIFE IN CLINICAL TRIALS OF PATIENTS WITH
MAJOR DEPRESSIVE DISORDER
Sapin C1, Le Lay A2, Llorca PM3, François C2
1Altipharm, Paris, France; 2H. Lundbeck A/S, Paris, France;
3CH Sainte-Marie, Clermont-Ferrand, France
OBJECTIVES: The published literature concerning
Health-Related Quality of Life (HRQL) in Major Depres-
sive Disorder (MDD) does not provide clear guidelines
between the use of generic and speciﬁc HRQL measures
from an evaluative perspective, though disease-speciﬁc
instruments are thought to be more sensitive to change.
Using data from two studies in which both generic 
and speciﬁc HRQL measurements were available, we
attempted to compare the relevance of both types of
instruments according to their sensibility to change and
the information provided. METHODS: Two randomised,
double blind, active-controlled, 8-week studies of esci-
talopram were used. In the ﬁrst study, 165 patients com-
pleted the generic SF-36 and the disease-speciﬁc Quality
of Life Depression Scale (QLDS). In the second study, 146
patients reported HRQL using the EuroQoL and QLDS
scales. Clinical efﬁcacy was assessed in both studies 
using the Montgomery-Asberg Depression Rating Scale
(MADRS). Results were adjusted for sustained remission
(from the assessment at which remission was achieved
until study termination) using the MADRS lesser than 
or equal to 12 criterion. RESULTS: In the ﬁrst study,
patients treated with Escitalopram showed signiﬁcant
improvement on all SF-36 subscales. Mean SF-36 changes
from baseline were signiﬁcantly different from 0. Esti-
mated effect sizes ranged from 0.52 (bodily pain) to 1.75
(mental health), indicating a moderate to large improve-
ment in HRQL. Using the same methodology, QLDS esti-
mated effect size was 1.04, indicating a large HRQL
improvement. In the study in which both EuroQoL and
QLDS scales were completed, signiﬁcant results were
obtained for both instruments. Estimated effect sizes were
0.79 and 0.98 for EuroQoL and QLDS respectively.
CONCLUSION: The results of these two studies clearly
demonstrated the ability of both instruments to be 
sensitive to changes. Yet, with similar effect sizes, the
generic SF-36 provided more information relative to the
different sub-scales affected than the disease speciﬁc
QLDS.
